Skip to Content

'
Mimi I. Hu, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Oncologic Endocrinology Fellowship Program, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director of Endocrine Center, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Bone Healthcare Program, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Clinical Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston, TX

Bio Statement

Dr. Mimi I. Hu graduated from Rice University with a degree in mechanical engineering. She obtained her medical degree from the University of Texas - Houston Health Sciences Center. She completed her residency and endocrine fellowship at the Baylor College of Medicine, where she also served as chief medical resident. After completion of her research fellowship at M. D. Anderson, she joined the faculty in 2007 in the department of Endocrine Neoplasia and Hormonal Disorders. Dr. Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma (differentiated and medullary), hereditary endocrine neoplasia disorders and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders.

Research Interests

Novel therapeutics for thyroid cancer
Medullary thyroid cancer
Bone and mineral metabolism disorders

Clinical Interests

Thyroid carcinoma - differentiated and medullary
Multiple endocrine neoplasia, Types 1 and 2
Bone and mineral metabolism disorders
Parathyroid disorders
Pituitary tumors
Endocrine effects of cancer and its therapies

For general clinic information, please visit the Department of Endocrine Neoplasia and Hormonal Disorders' contact information website listed below:

Contact Information

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 1461
Houston, TX 77030-4009
Room Number: FCT12.5022
Phone: 713-792-2841
Fax: 713-794-4065

Education & Training

Degree-Granting Education

2000 University of Texas Houston Health Science Center, Houston, TX, MD, Medicine
1993 Rice University, Houston, TX, BS, Mechanical Engineering

Postgraduate Training

8/2005-9/2008 Clinical Research Curriculum, Center for Clinical Research and Evidence-Based Medicine, University of Texas-Houston Medical School, Houston, TX, Kathleen Kennedy, MD
7/2004-6/2007 Clinical Fellowship, Endocrinology, Baylor College of Medicine, Houston, TX, Ashok Balasubramanyam
7/2001-6/2003 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX, Amir Halevy
6/2000-6/2001 Clinical Internship, Internal Medicine, Baylor College of Medicine, Houston, TX, Amir Halevy

Board Certifications

2016 Endocrinology, Diabetes and Metabolism
2014 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2007-8/2013
Chief Medical Resident, Division of Internal Medicine, Baylor College of Medicine, Houston, TX, 7/2003-6/2004

Administrative Appointments/Responsibilities

Member-Multidisciplinary Bone Health Center Steering Committee, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 7/2009-present
Member-Editorial Board for Department Newsletter/Website Committee, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2009-present
Member-Endocrine Center Steering Committee for the Institute of Personalized Cancer Therapy, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2008-2010
Member-Thyroid Cancer Survivorship Program, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present

Institutional Committee Activities

Division Representative, Graduate Medical Education Committee, 9/2013-present
Member, Clinical Research Committee 3, 9/2011-8/2012
Member, Pharmacy & Therapeutics Committee, 2/2011-present
Member, Clinical Research Committee 4, 9/2010-8/2011
Member, Clinical Research Committee 2, 9/2008-8/2010
Member, Graduate Medical Education Budget Subcommittee, 2008-present
Member, Graduate Medical Education Committee, 2008-8/2013

Honors and Awards

2014 Faculty Educator of the Month - May 2014, MD Anderson Cancer Center
2014 Best Doctors in America, Best Doctors
2012 U.S. News Top Doctors, U.S. News and World Report, Castle Connolly Medical Ltd
2011 ENDO 2011 Outstanding Abstract Award and Presidential Poster Competition Finalist, Encocrine Society 93rd Annual Meeting
2011 U.S. News Top Doctors, U.S. News and World Report, Castle Connolly Medical Ltd
2006 Travel Grant Award for Young Investigators, American Thyroid Association 77th Annual Meeting
1999 Alpha Omega Alpha Honor Society

Professional Memberships

American Association of Clinical Endocrinologists
Member, 2005-present
American College of Physicians
Member, 2000-2013
American Medical Association
Member, 1996-2012
American Society for Bone and Mineral Research
Member, 2007-present
American Society of Clinical Oncology
Member, 2007-2010
American Thyroid Association
Member, 2006-present
ASBMR Women in Bone and Mineral Research Committee
Council Member, 2008-2011
Endocrine Society
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Hu, MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for treatment of hypercalcemia of malignancy. J Clinical Endocrinology & Metabolism. e-Pub 6/2014. PMID: 24915117.
2. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aero-digestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24(5):918-22, 5/2014. e-Pub 3/2014. PMID: 24635127.
3. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu MI, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying AK, Grubbs EG. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. e-Pub 3/2014. PMID: 24617864.
4. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. e-Pub 3/2014. PMID: 24628550.
5. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 4/2014. PMCID: PMC4012968.
6. Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 98(11):E1813-9, 11/2013. e-Pub 9/2013. PMID: 24030942.
7. Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. J Natl Cancer Inst 105(18):1417-20, 9/2013. e-Pub 8/2013. PMCID: PMC3776443.
8. Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 8/2013. e-Pub 6/2013. PMID: 23796991.
9. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The non-investigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 1/2013. e-Pub 11/2012. PMCID: PMC3537108.
10. Rianon N, Alex G, Callender G, Jimenez C, Hu M, Grubbs E, Moreno M, Wathoo C, Petak S, Perrier N. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg 36(6):1320-6, 6/2012. PMID: 22278606.
11. Landry CS, Grubbs EG, Hernandez M, Hu MI, Hansen MO, Lee JE, Perrier ND. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg 147(4):338-44, 4/2012. e-Pub 12/19/2011. PMID: 22184134.
12. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center experience. Cancer 117(19):4381-9, 10/2011. e-Pub 3/2011. PMCID: PMC3134535.
13. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21(2):189-92, 2/2011. e-Pub 12/2010. PMCID: PMC3025175.
14. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 2008. PMCID: PMC2677083.

Invited Articles

1. Hu MI, Ying AK, Jimenez C. Update on medullary thyroid carcinoma. Endocrinology and Metabolism Clinics 43(2):423-442, 6/2014.
2. Rich TA, Hu MI, Martin JW, Perrier ND, Waguespack SG. CDC73-related disorders. GeneReviews at GeneTests, www.genetests.org, 5/2012. PMID: 20301744.
3. Hu MI, Gagel RF. Multiple endocrine neoplasia type 2. Translational Endocrinology & Metabolism 2(4):45-76, 12/2011.
4. Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol 9(5):1-3, 5/2011. PMID: 21685868.
5. Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract 17 Suppl 1:1-19, Mar-Apr, 3/2011. e-Pub 12/2010. PMID: 21134871.
6. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218(1):47-54, 2/2011. e-Pub 9/2010. PMID: 20946574.
7. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780, 2011. e-Pub 10/2011. PMCID: PMC3189619.
8. Hu MI, Lu H, Gagel RF. Cancer Therapies and Bone Health. Curr Rheumatol Rep 12(3):177-85, 6/2010. PMID: 20437119.
9. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3(2):75-88, 6/2009. e-Pub 5/2009. PMID: 19412668.
10. Jiménez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. PMID: 18502338.
11. Hu MI, Cote G, Gagel RF. RET gene: a therapeutic target in medullary thyroid carcinoma (within issue on "Recent advances in thyroid cancer"). Current Problems in Surgery 45(3):202-212, 2008.
12. Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep 5(4):170-8, 2007. PMID: 18430392.

Editorials

1. Hu MI, Cote GJ. Medullary thyroid carcinoma: who's on first? Thyroid 22(5):451-3, 5/2012. PMID: 22545752.

Abstracts

1. Hu MI, Glezerman I, Leboulleux X, Insogna KL, Gucalp RA, Misiorowski W, Yu BW, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Wang H, Braun A, Jain RK. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM). J Clin Oncology 31(suppl; abstr e20512), 5/2013.
2. Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack S, Ying A, Habra M, Thosani S, Hu M, Cabanillas M. Is second-line targeted therapy beneficial in patients (pts) with differentiated thyroid cancer (DTC) after first-line sorafenib (SOR) failure?. J Clin Oncology 31(suppl; abstr e17016), 5/2013.
3. Cabanillas ME, Holsinger FC, Sturgis E, Habra M, Davies MA, Munsell M, Busaidy N, Hu M, Sherman SI. Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC). J Clin Oncology 31(suppl; abstr TPS6100), 5/2013.

Book Chapters

1. Waguespack SG, Grubbs EG, Hu MI. Multiple endocrine neoplasia type 2. In: Clinical Genomics: Practical Applications in Adult Patient Care. McGraw Hill. In Press.
2. Hu MI, Jimenez C, Busaidy NL, Habra M. Long-term and late endocrine effects of cancer survivorship. In: Cancer Survivorship, 1st. Ed(s) LE Foxhall, MA Rodriguez. Springer, 2014. ISBN: 1493909851.
3. Dadu R, Ahn P, Holsinger FC, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 15th. UBM Medica: Connecticut, http://www.cancernetwork.com/cancer-management-app via http://itunes.apple.com, e-Book 2013.
4. Hu MI, Jimenez C, Cote GJ, Gagel RF. Medullary thyroid carcinoma. In: The Thyroid, 10th. Ed(s) Braverman L, Cooper D. Lippincott Williams & Wilkins: Philadephia, PA, 744-65, 2012.
5. Thosani S, Ahn P, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 14th. CMP Medica, http://www.cancernetwork.com/cancer-management-app via http://itunes.apple.com, e-Book 2012.
6. Alford E, Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 13th Edition. CMPMedica, 2011.
7. Hu M, Gagel RF. Multiple endocrine neoplasia type 2. In: Endocrinology, 6th edition. Ed(s) JL Jameson, LJ DeGroot. Saunders, 2010.
8. Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 12th Edition. CMPMedica, 51-70, 2010.
9. Hu MI, Sherman SI. Endocrine complications of head and neck surgery. In: Complications in Head and Neck Surgery, 2nd edition. Ed(s) Eisele, DW, 2009.
10. Hu MI, Yeung SJ, Gagel RF. Endocrine paraneoplastic syndromes. In: Internal Medicine Care of Cancer Patients. Ed(s) Escalante C, Yeung J, Gagel RF. BC Decker Inc; the Holland-Frei Series: Ontario, 2009.
11. Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont J. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 11th Edition. CMPMedica, 2009.
12. Hu MI, Gagel RF. Calcitonin gene family of peptides. In: Principles of Bone Biology, 3rd edition. Ed(s) Bilezikian J, Raisz L, Rodan G, 2008.

Last updated: 7/15/2014